Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
McGill University
$27,000.00
Exploring and Exploiting the Molecular Heterogeneity and Expression of B-Cell and other Hematologic Targettable Markers in Merkel Cell Carcinoma to Improve Diagnosis and Treatment
FY 2025-26
Summary
Merkel cell carcinoma (MCC) is a rare but highly aggressive neuroendocrine skin cancer, with the highest mortality rate among cutaneous malignancies. Historically thought to arise from Merkel cells in the epidermis, its true cellular origin remains debated. Recent evidence, including a study from our group, suggests that MCC may instead derive from alternative progenitor populations, such as pre-/pro-B Lymphocytes or other multipotent hematopoietic precursors. This study aims to elucidate the cellular origin and molecular architecture of MCC using both archived and prospectively collected tumour samples. More than 300 Canadian MCC specimens (FFPE and fresh biopsies)w ill be analyzed. Immunohistochemistry will assess co-expression of neuroendocrine markers (CK20, Chromogranin A) and hematopoietic markers (PAX5, CD20, CD10, CD19). In parallel, bulk RNA-sequencing will be performed, stratified by MCPyV status, immune status and tissue source. Transcriptomic findings will be validated through protein-level assays (Western blot, flow cytometry) on fresh specimens. Functional studies will be conducted in established MCC cell lines (MSD-1, WaGa), including cytokine stimulation (IL-2, IL-4, GM-CSF) and targeted gene knockdown (CRISPR-Cas9/siRNA) of candidates such as PAX5 and BCMA to evaluate their role in maintaining tumour identity. All samples will be de-identified and only minimal clinical data (Age, sex, disease stage, outcome) will be collected. This work builds on established protocols and addresses the under-representation of MCC in genomic databases By defining lineage-specific transcriptional programs and validating them functionally, this study may lead to improved diagnostic panels and novel therapeutic targets, particularly for immunosuppressed patients.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
572845
Name
Khalaf Roy
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Exploring and Exploiting the Molecular Heterogeneity and Expression of B-Cell and other Hematologic Targettable Markers in Merkel Cell Carcinoma to Improve Diagnosis and Treatment
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
B-Cell; Cellular Lineage; Mcpyv; Merkel Cell Carcinoma; Neuroendocrine; Tumour
Abstract
Merkel cell carcinoma (MCC) is a rare but highly aggressive neuroendocrine skin cancer, with the highest mortality rate among cutaneous malignancies. Historically thought to arise from Merkel cells in the epidermis, its true cellular origin remains debated. Recent evidence, including a study from our group, suggests that MCC may instead derive from alternative progenitor populations, such as pre-/pro-B Lymphocytes or other multipotent hematopoietic precursors. This study aims to elucidate the cellular origin and molecular architecture of MCC using both archived and prospectively collected tumour samples. More than 300 Canadian MCC specimens (FFPE and fresh biopsies)w ill be analyzed. Immunohistochemistry will assess co-expression of neuroendocrine markers (CK20, Chromogranin A) and hematopoietic markers (PAX5, CD20, CD10, CD19). In parallel, bulk RNA-sequencing will be performed, stratified by MCPyV status, immune status and tissue source. Transcriptomic findings will be validated through protein-level assays (Western blot, flow cytometry) on fresh specimens. Functional studies will be conducted in established MCC cell lines (MSD-1, WaGa), including cytokine stimulation (IL-2, IL-4, GM-CSF) and targeted gene knockdown (CRISPR-Cas9/siRNA) of candidates such as PAX5 and BCMA to evaluate their role in maintaining tumour identity. All samples will be de-identified and only minimal clinical data (Age, sex, disease stage, outcome) will be collected. This work builds on established protocols and addresses the under-representation of MCC in genomic databases By defining lineage-specific transcriptional programs and validating them functionally, this study may lead to improved diagnostic panels and novel therapeutic targets, particularly for immunosuppressed patients.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Khalaf, Roy
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~